Virological response to protease inhibitor therapy in an HIV clinic cohort

AIDS

Volumn 13, Issue 3, 1999, Pages 367-373

  Staszewski, Schlomo ^a   Miller, Veronica ^e   Sabin, Caroline ^b   Carlebach, Amina ^e   Berger, Anna Marie ^a   Weidmann, Eckhart ^c   Helm, Eilke B ^e   Hill, Andrew ^d   Phillips, Andrew ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Medizinische Klinik III   (Germany)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Glaxo Wellcome ^*

Author keywords

Cohort study; Predictors of viral load treatment response; Predictors of virological failure; Protease inhibitor treatment

Indexed keywords

CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; VIRUS RNA;

ARTICLE; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; REGRESSION ANALYSIS; VIRUS LOAD;

EID: 0033008399     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902250-00009     Document Type: Article

References (17)

1. BHIVA Guidelines Coordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
2. Panel on Clinical Practices for Treatment of HIV Infection (convened by Department of Health and Human Services and Henry Kaiser Family Foundation): Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1997, 128:1079-1100.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
4. Havlir DV, Richman DD: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996, 124:984-994.
5. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997, 349:1408-1409.
6. Hammer S, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-731.
7. Gullick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
8. Cox DR, Oakes D: Analysis of Survival Data. London: Chapman and Hall; 1984.
9. Cameron B, Heath-Chiozzi M, Kraveik S, et al.: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB6a].
10. Coebel F on behalf of the AVANTI Study Group: AVANTI 2. A randomized double blind comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs. AZT/3TC/indinavir in antiretroviral naive patients. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 211].
11. 3. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract LB6a],
12. Stellbrink HJ: Clinical and survival benefit of saquinavir in combination with zalcitabine and zidovudine in untreated/minimally treated HIV-infected patients. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 212].
13. Yu C, Chang Y, Greenberg SL, Clendenin NJ: Durability of virological response in patients with Viracept (Nelfinavir mesylate) in combination with zidovudine and lamivudine. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 410].
14. De Cruttola V, Hughes MD, Gilbert P, Phillips AN: New trial design issues in the era of maximal viral suppression. AIDS 1998, 12 (suppl) (in press).
15. Fätkenhcuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
16. Moyle G: Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996, 5:155-167.
17. 3. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 12237).